Resources Repository
-
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
Cost-Effectiveness Analysis | Health Systems | Priority Setting/Ethics | Infectious Diseases | Economics/Finance | Health/Medicine | North America -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Health Systems | Costing Methods | Health Outcomes | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ReviewPublication 2012Modeling Preventative Strategies Against HPV-Related Disease in Developed Countries
This review article is part of a special supplement on “Comprehensive Control of HPV Infections …
This review article is part of a special supplement on “Comprehensive Control of HPV Infections and Related Diseases.” At the time of its writing, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females had been introduced in most developed countries, supported by modeled evaluations that had almost universally found vaccination of pre-adolescent females to be cost-effective. Vaccination of pre-adolescent males had been shown to be cost-effective at a cost per vaccinated individual of ~US$400-500 if…
Cost-Effectiveness Analysis | Health Systems | Mathematical Models | Chronic Disease/Risk | Social Determinants | Health/Medicine | Global -
ArticlePublication 2012Value of Family Planning for Improving Maternal Health in Rural Afghanistan
This article, published in the Afghanistan Journal of Public Health, uses a model designed to …
This article, published in the Afghanistan Journal of Public Health, uses a model designed to simulate the natural history of pregnancy and associated maternal mortality and morbidity contextualized to Afghanistan to assess the cost-effectiveness of family planning in the rural Maywand district of Kandahar. Using total fertility rate, pregnancy-related complications, maternal mortality ratio, lifetime risk of maternal death, and proportionate mortality ratio as outcomes, the model finds that increasing family planning from 8% to 30-50% could…
Cost-Effectiveness Analysis | Policy/Regulation | Health Outcomes | Maternal/Reproductive Health | Health/Medicine | Asia & Pacific -
ArticlePublication 2011Model-Based Analyses to Compare Health and Economic Outcomes of Cancer Control: Inclusion of Disparities
In order to identify strategies that improve both population health and ensure its equitable distribution, …
In order to identify strategies that improve both population health and ensure its equitable distribution, the authors developed a typology of cancer disparities that considers types of inequalities among black, white, and Hispanic populations across different cancers. This paper reports on the typology using an existing disease simulation model of cervical cancer that was calibrated to clinical, epidemiological, and cost data in the United States and presents characteristics important for policy discussions. The typology proposed…
Cost-Effectiveness Analysis | Health Systems | Priority Setting/Ethics | State-Transition | Chronic Disease/Risk | Social Determinants | Clinical Care | Culture/Society | Health/Medicine | Science/Technology | North America -
ArticlePublication 2010Clinical Benefits, Costs, and Cost-Effectiveness of Neonatal Intensive Care in Mexico
This article reports on a study to estimate the clinical outcomes, costs, and cost-effectiveness of …
This article reports on a study to estimate the clinical outcomes, costs, and cost-effectiveness of neonatal intensive care in Mexico. The authors conducted a cost-effectiveness analysis using a decision analytic model of health and economic outcomes following preterm birth. Model parameters governing health outcomes were estimated from Mexican vital registration and hospital discharge databases, supplemented with meta-analyses and systematic reviews from the published literature. Costs were estimated on the basis of data provided by the…
Cost-Effectiveness Analysis | Health Systems | State-Transition | Child/Nutrition | Clinical Care | Health/Medicine | Latin America & Caribbean -
BookPublication 2003WHO Guide to Cost-Effectiveness Analysis
This 2003 guide provides a method of assessing the cost-effectiveness of health interventions for an …
This 2003 guide provides a method of assessing the cost-effectiveness of health interventions for an international audience. The authors aim to inform the policy maker and to maximize the generalizability of results across settings. Part I begins with a description of cost-effectiveness analysis. It then considers issues relating to study design, estimating costs, assessing health effects, discounting, uncertainty and sensitivity analysis, and reporting results. Part II provides examples to illustrate the principles in Part I. Detailed discussions…
Cost-Effectiveness Analysis | Health Systems | Priority Setting/Ethics | Costing Methods | Health Outcomes | Evidence Synthesis | Mathematical Models | Health/Medicine | Global